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Oral Presentations S183numbers of UCB cells, including T cells. We evaluated the feasi-
bility of generating UCB-derived CD19-specific T cells for clinical
infusion from the T cells in this residual. These T cells were elec-
troporated with CD19RCD28 CAR expressed as a Sleeping Beauty
(SB) transposon and propagated in the presence of IL-2 and IL-21
on g-irradiated CD19+ K562 artificial antigen presenting cells
(aAPC). The electroporated and propagated cells were a population
of CD8+ and CD4+ memory and effector T cells that exhibit
redirected CD19-dependent killing and cytokine production. The
UCB-derived CD19-specific T cells were further analyzed using
a new technology using the NanoString nCounter Analysis System,
a digital technology that is based on direct multiplexed measure-
ment of mRNA and therefore gene expression that offers a high
level of precision and sensitivity from a few number of cells.
This approach to manufacturing CD19-specific T cells and analy-
sis of mRNA expression profiles will be used to generate donor-
derived CD19-specific T cells that can be infused after UCBT as
an approach to enhance the graft-versus-tumor-effect without
increasing GvHD. The relative ease and low cost associated with
production of clinical grade DNA plasmids, electroporation, and
reproducible outgrowth of T cells stablely expressing CAR on
thawed g-irradiated MCB of aAPC, should enable facilities operat-
ing in compliance with cGMP for Phase I/II to implement adop-
tive immunotherapy trials using CAR+ T cells. By using the
scant numbers of residual UCB cells present after washing, we
have identified one potential way to overcome a major barrier to
UCB-derived T-cell therapies.75
IMPACT OF DONOR CHOICE ON PEDIATRIC DAY +100 TRANSPLANT
MORTALITY: THE PBMTC EXPERIENCE 2002-2004
Lehmann, L.E.1,2, Marcin, J.3, Scott, E.3, Ryan, R.5, Haut, P.6,
Schultz, K.4, Taylor, D.D.3 1Dana Farber Cancer Institute, Boston,
MA; 2Children’s Hospital, Boston, MA; 3University of California Davis,
Sacramento, CA; 4BC Children’s Hospital, Vancouver, BC, Canada;
5Children’s Mercy Hospital, Kansas City, MO; 6Riley Children’s Hospital,
Indianapolis, INBackground: A genotypically matched sibling is almost universally
the preferred donor source for pediatric patients undergoing alloge-
neic hematopoietic stem cell transplant (HSCT). Some patients lack-
ing a matched sibling donor will have a matched or mismatched
related donor identified. It is not clear whether in this setting a family
donor is preferable to an unrelated donor. Using the data base of the
Pediatric BoneMarrow Transplant Consortium from 2002-2004 we
evaluated 100 daymortality in 2696 patients\22 years of age receiv-
ing an non-syngeneic HSCT.
Results: The observed 100 day mortality for matched sibling do-
nors (n5 624) was 9.5%, for other matched family donors (n5 41)
12% and for mismatched sibling donors (n5 89) 19%. Univariate
analysis assigning a value of 1 for the 100 day mortality reported
for 939 autologous transplants from this cohort was performed.
There was no difference in mortality seen in patients transplanted
from amatched sibling donor (OR5 1.2,NS) or othermatched fam-
ily donor (OR5 1.6, NS). The use ofmismatched sibling donors and
matched or mismatched unrelated donors resulted in a significant in-
crease in Day 100 mortality (OR5 2.8-4.1, p\0.005). However, in
multivariate analysis incorporating 47 independent variables there
was a trend toward increased mortality as donor disparity increased.
Compared to those undergoing autologous transplant, patients re-
ceiving a transplant from a matched sibling donor had an OR of
2.3 (95% CI, 1.2-4.5), other matched family donor 3.6 (95% CI,
1.2-11.3), mismatched sibling donor 4.5 (95% CI, 2-10.2), matched
unrelated donor 6.4 (95% CI, 3.9-16.6) and mismatched unrelated
donor 7.8 (95% CI, 3-14.5).
Conclusion: When an HLA matched sibling donor is not avail-
able, the differences in acute mortality between alternative donor
options may be outweighed by other donor/patient considerations.
The use of a mismatched sibling donor or unrelated donor com-
pared to a matched family donor may confer an increased risk
that should be considered in the context of individual patient
circumstances.76
EXCELLENT SURVIVAL AFTER MATCHED UNRELATED DONOR STEM
CELL TRANSPLANTATION IN CHRONIC GRANULOMATOUS DISEASE
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A number of reports document the successful role of matched
related donor hematopoietic stem cell transplant (MRDHSCT)
in patients with Chronic Granulomatous Disease (CGD). Less cer-
tain is the safety and efficacy of HSCT from unrelated donors. We
report the use of HSCT in ten children with a matched related do-
nor (MRD) (n5 4) or a matched unrelated donor (MUD) (n5 6).
The median age of our group was 4.7 years (range: 0.9-8.4 years)
with x-linked (n5 8) or autosomal recessive (n5 2) disease over
a 6 year period (2003-2009). Despite treatment with anti-bacterial
and anti-fungal medications and gamma interferon, nine children
had significant clinical infections before transplant including: oste-
omyelitis (n5 2), lung/liver abscess requiring surgical intervention
(n5 3), aspergillus pneumonia (n5 3) and staphylococcus/
B.cepaciae sepsis/shock (n5 2). The conditioning regimen for pa-
tients receiving a MRD product consisted of busulfan(1 mg/kg,
AUC 900 – 1200 mmol/min/L), cyclophosphamide(90 mg/kg) and
cytarabine(2grams/m2). Patients receiving a MUD product were
conditioned with busulfan(1 mg/kg, AUC 900 – 1200 mmol/min/
L), cychlophosphamide(200 mg/kg) and fludarabine(120 mg/m2).
GvHD prophylaxis consisted of cyclosporine and methrotrexate
for MUD recipients and cyclosporine and prednisone for MRD re-
cipients. Campath (anti-CD52) was used to improve engraftment
and prevent aGvHD in all the patients. The median total nucleated
cell dose was 6108/kg. The median time to neutrophil and plate-
let recovery was 18 days (range, 12-40 days) and 16 days (range, 12-
26 days) respectively. The majority of the patients (n5 8) achieved
100% neutrophil engraftment except two (68, 73%) but all have
sustained correction of their neutrophil oxidative burst defect.
Four patients developed grade I aGVHD requiring only topical
treatment. None of the patients developed grade II-IV aGvHD.
There has been no incidence of cGvHD. Among the post trans-
plant morbidities we report: busulfan related seizures (n5 1), BK
hemorrhagic cystitis (n5 1), and bacterial/fungal pneumonia
(n5 2). None of the patients developed organ failure during the
post transplant period. All patients are currently living with follow
up ranging from 42 days to 6 years. In our cohort, the outcome of
MUDSCT is very feasible and equivalent to MRDSCT and should
be considered early in the course of CGD to cure the underlying
neutrophil defect and improve quality of life in the absence of
a MRD.77
PERIPHERAL BLOOD IS THE STEM CELL SOURCE OF CHOICE FOR RE-
DUCED INTENSITY STEM CELL TRANSPLANT IN CHILDREN
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Reduced intensity conditioning (RIC) enables SCT in children
with pre-existing organ toxicity. However, there are concerns about
mixed chimerism(MC) in the long term that is sometimes not
sufficient for cure. In a cohort of 148 patients undergoing RIC
SCT (Fludarabine 150 mg/m2, Melphalan 140 mg/m2, Campath
1H 0.6-1 mg/kg) we compared chimerism between those who re-
ceived BM (n5 109) Vs PBSC (n5 41). Median age at transplant
was 3.6 years and median follow-up was 4.7 years.The majority
were transplanted for primary immunodeficiency disorders
(n5 120) and donors were MUD (n5 67), mMUD (n5 45), MSD
(n5 17),MFD (n5 14) andmMFD (n5 8). Survival was equivalent,
70% for BMand 75% for PBSC. Incidence of aGVHD$ grade 2 was
higher with PBSC (40% vs 20% for BM) but the incidence of chronic
GVHD was low (10%).
S184 Oral PresentationsChimerism studies were done using STR at 1, 3, 6, 9 and 12
months post transplant and 3 monthly thereafter. All but one child
engrafted but 4 children had early autologous reconstitution. At 1
year post SCT65%, 9%, 9%and 7%had complete donor chimerism
(CC), highMC (50-95%donor chimerism), lowMC (10-49% donor
chimerism) and very lowMC (\10% donor chimerism) respectively
and these were stable at last follow-up. All childrenwithCC and high
MC are cured of their disease. 26 children (17%) had low or very low
MC. The incidence of low and very lowMCwas significantly higher
with BM (24/109,22%) than with PBSC (2/41,5%).Children with
low and very low levelMChad a poorer prognosis: 5/26 needed a sec-
ond transplant, 3/26 died, 2 had DLI, 1 CD34 top-up, 1 has ongoing
poor immune reconstitution. In conclusion, use of PBSC leads to
good long term chimerism with acceptable GVHD and we advocate
that PBSC should be the stem cell source of choice in RIC SCT in
children.78
NOD2/CARD POLYMORPHISM AND THE DEVELOPMENT OF IDIOPATHIC
PULMONARY SYNDROME
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Background: In hematopoietic stem cell transplantation (HSCT)
the occurrence of single nucleotide polymorphisms (SNPs)
within the NOD2/CARD15 gene are associated with higher
susceptibility for graft-versus-host disease (GvHD). Idiopathic
pulmonary syndrome (IPS) is a non-infectious early onset lung
disease (\100days) after HSCT and associated with high mortal-
ity rates. Exact pathogenesis is unknown, but IPS could be con-
sidered as an allo-reactive disease. We retrospectively studied the
clinical impact of NOD2-variants in pediatric HSCT patients
with IPS.
Methods: All patients transplanted between 2004 and 2006 in the
UMCUwere included. For all recipient-donor pairs, mutation anal-
ysis for SNPs 8, 12 and 13 of the NOD2-gene was performed. IPS
was defined as respiratory symptoms with infiltrative changes on
chest X-ray without a direct infectious cause identified (excluding
a respiratory virus). An uni- and multivariable risk factor analyses
was performed using logistic regression and Cox proportional
Hazards.
Results: 57 HSCT patients (29 malignant and 28 for non-malignant
indication) were transplanted with 33 matched and 24 mismatched
donors. Median follow up was 19 months (8-36). The actual proba-
bility of disease free survival was 71%. IPS occurred in 9 patients at
a median of 7 weeks post-HSCT (range 3-12) of whom 4 died. NOD
polymorphisms were found in 6 recipients, 5 donors and in 4 both
donor and recipient. In multivariate regression analysis presence of
a respiratory virus after transplant (p5 0.032, OR 14.41, range
1.27-164.12) and presence of a NOD2-variant (in donor and/or
recipient: p5 0.046, OR 9.15, range 1.04 -80.44) were independent
variables influencing the endpoint IPS.
Conclusion: NOD2 polymorphisms may impact the development
of IPS in addition to the presence of respiratory viral infections. Al-
though more research is warranted on this topic it suggests that
avoiding NOD2 polymorphisms in donors as well as reducing the
pulmonary epithelial damage by screening for viral infections and/
or preventing viral infections prior to SCTmay be important to pre-
vent IPS.79
UK EXPERIENCE OF TREOSULFAN-BASED CONDITIONING REGIMENS IN
CHILDREN WITH PRIMARY IMMUNODEFICIENCY OR SEVERE IMMUNE
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Treosulfan is a bi-functional alkylating agent which causes less
VOD than busulphan and does not require anticonvulsant pro-
phylaxis and drug monitoring. We report the use of treosulfan in
70 children undergoing HCT for PID at two supraregional
transplant centres in the UK. Children received 42 g/m2 or 36 g/m2
treosulfan in combination with either cyclophosphamide 200 mg/kg
(30) or fludarabine 150 mg/m2 (40). All received Campath 1 H
0.3 mg/kg to1.0 mg/kg total dose except those with matched sibling
donors (n5 8), haploidentical CD3/CD19 depleted grafts (n5 3),
CD34+ selected graft with OKT3 (1) and 4 cords (3 of whom had
ATG).
Diagnoses were as follows: severe combined immunodeficiency
(26), Omenn’s Syndrome (7), Wiskott Aldrich syndrome (7), HLH
(5), leukocyte adhesion deficiency (4), chronic granulomatous dis-
ease (3), severe immune dysregulation (3), other PID (15).
Age at transplant ranged from 5 weeks to 14 years 8 months
(median 9 months). 47 patients were 12 months or younger.
Donors were as follows: MSD (8 -1 cord); MFD (13); haploident-
ical (4); URD (45:HLA matched 7-10/10). 16 of 45 were cords (7-
10/10 HLA matched). Follow up is 2- 59 months (median 16
months).
Overall survival was 81%. 13 children died: 6/40 in the treo-
sulfan/fludarabine group and 7/30 in the treosulfan/cyclophos-
phamide group- HLH disease D-1, graft rejection and CMV,
infection (4), GVHD, GVHD+infection etc. Skin toxicity was
common. VOD occurred in 2 children in combination with
cyclophosphamide and both had enterovirus in the gut. 2 patients
rejected (MHC II deficiency successfully retransplanted, ALPS
patient died of CMV before retransplant). Of patients more
than 6 months post transplant 19/28 (68%) who had treosul-
fan/fludarabine and 14/22 (64%) treosulfan/cyclophosphamide
have 100% donor chimerism. The remainder have stable mixed
chimerism.
Outcome is good with low regimen related toxicity. Treosulfan
plus fludarabine was particularly well tolerated. Immune reconstitu-
tion and chimerism were equivalent to busulphan containing regi-
mens. Long-term follow up is required.80
HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX (HCT-
CI) PREDICTS TRANSPLANT OUTCOMES IN PEDIATRIC PATIENTS
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Despite major advances in the field of hematopoietic cell trans-
plant (HCT) in recent years, significant life-threatening complica-
tions still occur. Quantifying this risk for individual patients,
however, is challenging. The HCT-CI combines important comor-
bidities with varying effect on treatment related morbidity and
mortality and combines them into one score. It has been confirmed
as a useful tool in adults undergoing HCT, but has not yet been
validated in children. We conducted a retrospective cohort study
of 252 consecutive pediatric patients undergoing their first alloge-
neic HCT at 4 large centers between January 2008 and May 2009.
Pre-transplant comorbidities were scored prospectively for each
patient using the HCT-CI. The impact of the HCT-CI score on
non-relapse mortality (NRM) and overall survival (OS) was then
analyzed. Underlying diagnoses included leukemia (n5 110),
immune deficiency (n5 63), storage disorders (n5 24), aplastic ane-
mia (n5 22), Fanconi anemia (n5 18), benign hematologic abnor-
malities (n5 9) and other (n5 6). The median age at transplant
was 6 years (range 0.1-20). Donor sources included matched related
donor (n5 74), mismatched related donor (n5 21), HLA matched
unrelated donor (n5 75), mismatched unrelated donor (n5 34)
